Literature DB >> 15260924

The relationship between erectile dysfunction and lower urinary tract symptoms: epidemiological, clinical, and basic science evidence.

Kevin T McVary1, Kevin E McKenna.   

Abstract

Lower urinary tract symptoms (LUTS) and sexual dysfunction are highly prevalent in aging men. Both conditions also are significant contributors to overall quality of life. New data have emerged to indicate potential links in epidemiological, physiologic, pathophysiologic, and treatment aspects of these two entities. There are numerous publications based on sophisticated community and clinical-based data, suggesting a strong and consistent association between LUTS and erectile dysfunction (ED). The association is supported by the consistent linear relationship of more severe LUTS with more severe ED. The link between ED and LUTS has biologic plausibility given the four leading theories of how these diseases inter-relate.

Entities:  

Mesh:

Year:  2004        PMID: 15260924     DOI: 10.1007/s11934-004-0047-1

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   2.862


  37 in total

1.  Sildenafil influences lower urinary tract symptoms.

Authors:  K Sairam; E Kulinskaya; T A McNicholas; G B Boustead; D C Hanbury
Journal:  BJU Int       Date:  2002-12       Impact factor: 5.588

2.  THE INCIDENCE OF BENIGN PROSTATIC HYPERPLASIA AND PROSTATIC CARCINOMA IN CIRRHOSIS OF THE LIVER.

Authors:  M C ROBSON
Journal:  J Urol       Date:  1964-10       Impact factor: 7.450

3.  The norepinephrine tissue concentration and neuropeptide Y immunoreactivity in genitourinary organs of the spontaneously hypertensive rat.

Authors:  Y C Tong; Y C Hung; S N Lin; J T Cheng
Journal:  J Auton Nerv Syst       Date:  1996-01-05

Review 4.  Age-related erectile and voiding dysfunction: the role of arterial insufficiency.

Authors:  T Tarcan; K M Azadzoi; M B Siroky; I Goldstein; R J Krane
Journal:  Br J Urol       Date:  1998-12

5.  Growth of the rat prostate gland is facilitated by the autonomic nervous system.

Authors:  K T McVary; A Razzaq; C Lee; M F Venegas; A Rademaker; K E McKenna
Journal:  Biol Reprod       Date:  1994-07       Impact factor: 4.285

6.  Specificity of the American Urological Association voiding symptom index: comparison of unselected and selected samples of both sexes.

Authors:  T C Chai; W D Belville; E J McGuire; L Nyquist
Journal:  J Urol       Date:  1993-11       Impact factor: 7.450

7.  Prevalence of erectile dysfunction and associated factors among men without concomitant diseases: a population study.

Authors:  A Nicolosi; D B Glasser; E D Moreira; M Villa
Journal:  Int J Impot Res       Date:  2003-08       Impact factor: 2.896

8.  Combination therapy using oral alpha-blockers and intracavernosal injection in men with erectile dysfunction.

Authors:  S A Kaplan; R B Reis; I J Kohn; R Shabsigh; A E Te
Journal:  Urology       Date:  1998-11       Impact factor: 2.649

Review 9.  Benign prostatic hyperplasia. The scope of the problem.

Authors:  J T Grayhack
Journal:  Cancer       Date:  1992-07-01       Impact factor: 6.860

10.  Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study.

Authors:  H A Feldman; I Goldstein; D G Hatzichristou; R J Krane; J B McKinlay
Journal:  J Urol       Date:  1994-01       Impact factor: 7.450

View more
  15 in total

1.  Medical therapy for benign prostatic hyperplasia: new terminology, new concepts, better choices.

Authors:  Steven A Kaplan
Journal:  Rev Urol       Date:  2006

Review 2.  Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia.

Authors:  Chris Olesovsky; Anil Kapoor
Journal:  Ther Adv Urol       Date:  2016-05-26

3.  Cardiovascular autonomic neuropathy, erectile dysfunction and lower urinary tract symptoms in men with type 1 diabetes: findings from the DCCT/EDIC.

Authors:  Rodica Pop-Busui; Jim Hotaling; Barbara H Braffett; Patricia A Cleary; Rodney L Dunn; Catherine L Martin; Alan M Jacobson; Hunter Wessells; Aruna V Sarma
Journal:  J Urol       Date:  2015-01-10       Impact factor: 7.450

Review 4.  The role of phosphodiesterase type-5 inhibitors in treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.

Authors:  Mehmet Umul; Tekin Ahmet Serel
Journal:  Turk J Urol       Date:  2013-12

5.  Correlation between lower urinary tract symptoms and premature ejaculation in Korean men older than 40 years old [corrected].

Authors:  Jae Doo Um; Dong Il Kang; Jang Ho Yoon; Kweon Sik Min
Journal:  Korean J Urol       Date:  2012-03-19

6.  Measurement properties of the benign prostatic hyperplasia impact index in tadalafil studies.

Authors:  Mallik Angalakuditi; Rita F Seifert; Risa P Hayes; Michael P O'Leary; Lars Viktrup
Journal:  Health Qual Life Outcomes       Date:  2010-11-12       Impact factor: 3.186

7.  Impact of lower urinary tract symptoms/benign prostatic hyperplasia treatment with tamsulosin and solifenacin combination therapy on erectile function.

Authors:  Deok Ha Seo; Sung Chul Kam; Jae Seog Hyun
Journal:  Korean J Urol       Date:  2011-01-24

Review 8.  The impact and management of sexual dysfunction secondary to pharmacological therapy of benign prostatic hyperplasia.

Authors:  Jason Gandhi; Steven J Weissbart; Noel L Smith; Steven A Kaplan; Gautam Dagur; Anna Zumbo; Gargi Joshi; Sardar Ali Khan
Journal:  Transl Androl Urol       Date:  2017-04

9.  Effect of intensive glycemic control and diabetes complications on lower urinary tract symptoms in men with type 1 diabetes: Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study.

Authors:  Stephen K Van Den Eeden; Aruna V Sarma; Brandy N Rutledge; Patricia A Cleary; John W Kusek; Leroy M Nyberg; Kevin T McVary; Hunter Wessells
Journal:  Diabetes Care       Date:  2009-01-26       Impact factor: 19.112

10.  Tadalafil in the treatment of erectile dysfunction.

Authors:  Robert M Coward; Culley C Carson
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.